MabPlex opens new manufacturing facility in Yantai, China

MabPlex International inaugurated a new Phase III and commercial manufacturing facility in Yantai, Shandong, China. The facility adds 400,000 ft² of cGMP space with six cell culture suites and four purification suites.

“With a growing number of novel and increasingly complex drug constructs in early development pipelines and new targeted therapies, such as ADCs, in late stage development and moving to commercialization, there is”adcreview.com

• 1 source
• adcreview.comMabPlex Opens New Phase III and Commercial Manufacturing Facility » ADC ReviewPeter HoflandDec 13, 2018

Summarized from public sources; check the original articles before acting on it.